Terms: = Endocrine gland cancer AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Clinical Outcome
24 results:
1. The Role of Activation of PI3K/AKT/mTOR and RAF/MEK/erk Pathways in Aggressive Pituitary Adenomas-New Potential Therapeutic Approach-A Systematic Review.
Derwich A; Sykutera M; Bromińska B; Rubiś B; Ruchała M; Sawicka-Gutaj N
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446128
[TBL] [Abstract] [Full Text] [Related]
2. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer.
Xiong Q; Zhou Y; Zhang S; Zhang Y; Xu Y; Yang Y; Zhou C; Zeng Z; Han J; Zhu Q
Cancer Med; 2023 May; 12(9):10961-10978. PubMed ID: 37062069
[TBL] [Abstract] [Full Text] [Related]
3. miRNA‑7515 suppresses pancreatic cancer cell proliferation, migration and invasion via downregulating IGF‑1 expression.
Lei S; Zeng Z; He Z; Cao W
Oncol Rep; 2021 Sep; 46(3):. PubMed ID: 34296285
[TBL] [Abstract] [Full Text] [Related]
4. Phosphoproteomics identify arachidonic-acid-regulated signal transduction pathways modulating macrophage functions with implications for ovarian cancer.
Dietze R; Hammoud MK; Gómez-Serrano M; Unger A; Bieringer T; Finkernagel F; Sokol AM; Nist A; Stiewe T; Reinartz S; Ponath V; Preußer C; von Strandmann EP; Müller-Brüsselbach S; Graumann J; Müller R
Theranostics; 2021; 11(3):1377-1395. PubMed ID: 33391540
[TBL] [Abstract] [Full Text] [Related]
5. Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial-mesenchymal transition and cancer stem cell-like properties by modulating forkhead box protein M1.
Cao J; Li J; Sun L; Qin T; Xiao Y; Chen K; Qian W; Duan W; Lei J; Ma J; Ma Q; Han L
Mol Oncol; 2019 Feb; 13(2):228-245. PubMed ID: 30367545
[TBL] [Abstract] [Full Text] [Related]
6. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
[TBL] [Abstract] [Full Text] [Related]
7. Expression of the scaffold connector enhancer of kinase suppressor of Ras 1 (CNKSR1) is correlated with clinical outcome in pancreatic cancer.
Quadri HS; Aiken TJ; Allgaeuer M; Moravec R; Altekruse S; Hussain SP; Miettinen MM; Hewitt SM; Rudloff U
BMC Cancer; 2017 Jul; 17(1):495. PubMed ID: 28732488
[TBL] [Abstract] [Full Text] [Related]
8. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and erk pathways.
Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
[TBL] [Abstract] [Full Text] [Related]
9. Involvement of AF1q/MLLT11 in the progression of ovarian cancer.
Tiberio P; Lozneanu L; Angeloni V; Cavadini E; Pinciroli P; Callari M; Carcangiu ML; Lorusso D; Raspagliesi F; Pala V; Daidone MG; Appierto V
Oncotarget; 2017 Apr; 8(14):23246-23264. PubMed ID: 28423573
[TBL] [Abstract] [Full Text] [Related]
10. Asporin promotes pancreatic cancer cell invasion and migration by regulating the epithelial-to-mesenchymal transition (EMT) through both autocrine and paracrine mechanisms.
Wang L; Wu H; Wang L; Zhang H; Lu J; Liang Z; Liu T
Cancer Lett; 2017 Jul; 398():24-36. PubMed ID: 28400334
[TBL] [Abstract] [Full Text] [Related]
11. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid cancer.
Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF
J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748
[TBL] [Abstract] [Full Text] [Related]
12. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
[TBL] [Abstract] [Full Text] [Related]
13. The flavonoid p-hydroxycinnamic acid exhibits anticancer effects in human pancreatic cancer MIA PaCa-2 cells in vitro: Comparison with gemcitabine.
Yamaguchi M; Murata T; El-Rayes BF; Shoji M
Oncol Rep; 2015 Dec; 34(6):3304-10. PubMed ID: 26397991
[TBL] [Abstract] [Full Text] [Related]
14. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
[TBL] [Abstract] [Full Text] [Related]
15. Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach.
Itamochi H; Oumi N; Oishi T; Taniguchi F; Shoji T; Fujiwara H; Sugiyama T; Suzuki M; Kigawa J; Harada T
Int J Gynecol Cancer; 2015 May; 25(4):570-6. PubMed ID: 25756405
[TBL] [Abstract] [Full Text] [Related]
16. Rac1 expression in epithelial ovarian cancer: effect on cell EMT and clinical outcome.
Leng R; Liao G; Wang H; Kuang J; Tang L
Med Oncol; 2015 Feb; 32(2):329. PubMed ID: 25585684
[TBL] [Abstract] [Full Text] [Related]
17. Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer.
Qin R; Smyrk TC; Reed NR; Schmidt RL; Schnelldorfer T; Chari ST; Petersen GM; Tang AH
Br J Cancer; 2015 Feb; 112(3):514-22. PubMed ID: 25584484
[TBL] [Abstract] [Full Text] [Related]
18. Novel synthetic oleanane triterpenoid AMR-MeOAc inhibits K-Ras through erk, Akt and survivin in pancreatic cancer cells.
Rabi T; Venkatanarashiman M
Phytomedicine; 2014 Mar; 21(4):491-6. PubMed ID: 24215674
[TBL] [Abstract] [Full Text] [Related]
19. Phosphorylation status of heat shock protein 27 plays a key role in gemcitabine-induced apoptosis of pancreatic cancer cells.
Nakashima M; Adachi S; Yasuda I; Yamauchi T; Kawaguchi J; Itani M; Yoshioka T; Matsushima-Nishiwaki R; Hirose Y; Kozawa O; Moriwaki H
Cancer Lett; 2011 Dec; 313(2):218-25. PubMed ID: 21999932
[TBL] [Abstract] [Full Text] [Related]
20. Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/erk and JNK pathways.
Chang MC; Chen CA; Chen PJ; Chiang YC; Chen YL; Mao TL; Lin HW; Lin Chiang WH; Cheng WF
Biochem J; 2012 Mar; 442(2):293-302. PubMed ID: 21999204
[TBL] [Abstract] [Full Text] [Related]
[Next]
